Inactivation of Suv39h1 Enhances Anti-Tumor Immune Response by Increasing T Cell Activity and Decreasing T Cell Exhaustion During Anti-PD-1 Treatment
PARIS, July 6, 2022 — Mnemo Therapeutics, a biotechnology company developing transformational immunotherapies, today announced a publication in Nature Communications demonstrating that the histone lysine methyltransferase enzyme Suv39h1 plays not…